People: Fortis Healthcare Ltd (FOHE.NS)

FOHE.NS on National Stock Exchange of India

123.25INR
2:43am EDT
Price Change (% chg)

Rs-1.35 (-1.08%)
Prev Close
Rs124.60
Open
Rs125.00
Day's High
Rs126.40
Day's Low
Rs121.80
Volume
353,897
Avg. Vol
523,149
52-wk High
Rs129.30
52-wk Low
Rs92.75

Search Stocks

Summary

Name Age Since Current Position

Malvinder Singh

2012 Executive Chairman of the Board

Vishal Bali

45 2012 Group Chief Executive Officer

Shivinder Singh

2012 Executive Vice Chairman of the Board

Sandeep Puri

2013 Chief Financial Officer

Aditya Vij

2011 Chief Executive Officer, India

Paul Li

2012 Chief Executive Officer - Quality Healthcare Medical Services, Hong Kong

Poh Lan Tan

Chief Executive Officer of Fortis Healthcare, Singapore

Rahul Ranjan

Compliance Officer, Company Secretary

Simmardeep Gill

Chief Operating Officer - Fortis Clinique Darne, Mauritius

Capri Jalota

General Manager - Operations, SRL Diagnostics, UAE

Daphne Khoo

Global Chief Medical Officer

K. Srivatsan

Chief Financial Officer of Fortis Healthcare International

Udai Dhawan

2014 Non-Executive Non Independent Director

Sunil Godhwani

2009 Non-Executive Non-Independent Director

Harpal Singh

63 2007 Non-Executive Non-Independent Director

Lynette Brown

2014 Additional Non-Executive Independent Director

Gurcharan Das

68 2000 Non-Executive Independent Director

Joji Gill

2012 Non-Executive Independent Director

Preetinder Joshi

65 1998 Non-Executive Independent Director

Pradeep Raniga

2012 Non-Executive Independent Director

Brian Tempest

63 2011 Non-Executive Independent Director

Anurag Kalra

IR Contact Officer

Biographies

Name Description

Malvinder Singh

Mr. Malvinder Mohan Singh is an Executive Chairman of the Board of the Company. He is one of the Promoters, graduated in Economics from St. Stephen’s College, Delhi and holds an MBA degree from the Fuqua School of Business, Duke University, U.S.A. Prior to this, Mr. Malvinder was the Chairman, Managing Director and CEO of Ranbaxy Laboratories Ltd. Mr. Malvinder put Ranbaxy in a position of leadership and consummated over 14 inorganic deals across geographies in less than two years. He unlocked value in Ranbaxy’s business model and focussed the Company on future growth by monetizing on-going patent challenges, investing resources in high growth emerging markets and forging strategic research alliances with global big pharma. He has been responsible for advising and counseling management on corporate decisions, providing strategic guidance and overseeing management of the business and ensuring ethical behaviour. He is a member of the Young Global Leaders Forum (YGL), an initiative of the World Economic Forum (WEF). He is also a member of the board of visitors at the Fuqua School of Business, Duke University and serves on the board of the INSEAD Global India Council. A member of the Board of Trade, constituted by the Ministry of Commerce & Industry, Government of India, from 2004 to 2009, Mr. Malvinder advises the Government on critical Policy issues relating to the country’s Foreign Trade, with the objective of significantly advancing India’s exports. Mr. Malvinder is a member of the Board of the Indian Council for Research on International Economic Relations (ICRIER).

Vishal Bali

Mr. Vishal Bali is Group Chief Executive Officer of the Company. Vishal has dedicated more than 2 decades in building global healthcare delivery organizations and his previous assignments include spearheading the growth of Wockhardt Hospitals as one of the largest specialty hospital chains in India as its CEO & MD. His expertise in successfully integrating healthcare strategy, operations and management through Information technology has set industry benchmarks. Vishal completed his Bachelors in Science and Masters in Business Administration from Bombay University and completed an advance program in hospital management from Boston. He sits on the board of leading healthcare organisations and is an invited member of the Strategic Initiatives group of Joint Commission International, US and on the Global Agenda Healthcare Council of the World Economic Forum. His keen interest in education and globalisation of healthcare takes him to leading Healthcare Education Institutes and Business Schools globally, which includes a case study at the Harvard Business School. He is an active member of various Industry bodies and globally recognized industry public speaker.

Shivinder Singh

Mr. Shivinder Mohan Singh is an Executive Vice Chairman of the Board of the Company. An alumnus of Doon School and an Honours Graduate in Mathematics from St. Stephens College, Delhi, Mr. Shivinder has done his MBA with specialization in health sector management from the Duke University Business School, USA. Mr. Shivinder Mohan Singh is also the Managing Director of Escorts Heart Institute And Research Centre Limited and is also one of the principal promoters and Director on the boards of Religare Enterprises Limited, Super Religare Laboratories Limited and Fortis Clinical Research Limited. He was, till recently, one of the key promoters of Ranbaxy Laboratories Limited and served as Director on the Board of the pharma

Sandeep Puri

Mr. Sandeep Puri is Chief Financial Officer of the Company. He is a member of the Institute of Chartered Accountants of India, joined Fortis Healthcare from Ranbaxy Laboratories Ltd. where he had a long stint of 21 years. While with Ranbaxy he worked at various positions in Russia, South Africa, China, Romania and United Kingdom. His last assignment was as the Regional Finance Director - Europe. In this role he was working with Regional and Functional Directors, enabling business delivery by providing leadership in finance function for 13 operational clusters in Europe covering 23 markets. Sandeep joined Fortis Group in March, 2012 as Chief Financial Officer. As a senior member of the management team, Sandeep is responsible for driving the finance function of the Indian Operations and supporting value creation for the Organisation. In addition, he will provide leadership to the global consolidation process and reporting of financials of the company as per IGAAP statutory requirements. As an ethical watchdog within the Group, he also works towards creating concrete measures to maintain and protect a transparent and a well-balanced system of corporate governance that goes beyond just compliance.

Aditya Vij

Mr. Aditya Vij is Chief Executive Officer, India of the Company. He is a Chartered Accountant from Institute of Chartered Accountants of India and an MBA from International Institute for Management Development (IMD), Lausanne, Switzerland. He has rich management experience spanning three decades in the corporate world with a proven track record of developing and turning around businesses in various leadership positions. Currently, he is the CEO of Fortis Healthcare Ltd., prior to which he was with Punj Lloyd where he held the position of Group President - Defence, a role in which he was responsible for setting up the Defence and Nuclear Power verticals for the Group. Prior to joining Punj Lloyd, Aditya had a distinguished innings of 18 years with General Motors, across five countries in Europe and Asia. Some of the key positions he held with GM include General Director - Opel Southeast Europe, Hungary, Chairman & Managing Director - GM India and Regional Executive Director - Nordic, Benelux & Switzerland. Among his significant achievements at GM were the turnaround of the India business into a profitable entity, the successful launch of the Chevrolet brand in India, the expansion of production capacity at the car manufacturing plants several-fold, the establishment of an engineering & R&D Centre for Global competitiveness and the setting up of a shared services centre for GM Units worldwide.

Paul Li

Mr. Paul Li is Chief Executive Officer - Quality Healthcare Medical Services, Hong Kong of the Company. Prior to joining Quality Healthcare, Paul spent 6 years with Cephalon, and his last assignment was the VP for the Pharmaceutical Operations, International. Paul was also with Merck Co. where he held positions of increasing responsibility as the Managing Director for China, VP for Asia North, and VP for Asia. Prior to Merck, Paul was the commercial director for Abbott Taiwan. Paul started his career with Eli Lilly in Hong Kong; and went through a few overseas marketing and human resources management assignments in the US and other Asian countries. Paul has impeccable senior level leadership credentials in the, healthcare industry. In addition to the regional and country general management skills for the international markets, he has extensive experience in strategic planning, M&A strategy and strategic partnership, organizational development and human resources management, start up and market entry strategy as well as business process improvement and implementation. Paul has serviced as board of directors of a few Chinese companies and senior advisor of a private equity firm. He has also successfully worked in multiple countries and cultures, and has resided in the US, China, Taiwan, Singapore and Hong Kong.

Poh Lan Tan

Ms. Tan Poh Lan is Chief Executive Officer of Fortis Healthcare, Singapore of the Company. In this role, she is responsible for the healthcare business in Singapore, currently comprising Fortis Colorectal Hospital and RadLink-Asia Pte Ltd. She will be actively involved in growing the business in the country to increase the company's profile. Poh Lan has more than 25 years of experience in the government and private healthcare settings in both Singapore and Vietnam with skills in operations, personnel management, performance/quality improvement and business development. A strong believer of teamwork, she works in collaboration with others toward mutual success of the team's objectives. She has a management style based on strong interpersonal and human relations skills and has the ability to build a motivated team with a strong customer focus. Prior to joining Fortis, Poh Lan was the Chief Executive Officer of Vinmec International Hospital, Hanoi - a 500 bed hospital that was recently commissioned and started operations in January 2012. Before this, she has assumed senior leadership roles in Parkway Healthcare as the Chief Executive Officer of Gleneagles Hospital, Chief Executive Officer of East Shore Hospital and Assistant General Manager of Mount Elizabeth Hospital.

Rahul Ranjan

Mr. Rahul Ranjan is Compliance Officer, Company Secretary of the Company.

Simmardeep Gill

Dr. Simmardeep Singh Gill is Chief Operating Officer - Fortis Clinique Darne, Mauritius of the Company. He is a medical graduate and holds a Post-Graduation in Healthcare and Hospital Management. He has over twelve years of experience in the healthcare industry, ten of which have been at Fortis Healthcare. Before taking over as Chief of Fortis Clinique Darné, he was heading Fortis Hospitals, Bangalore, and was instrumental in turning it around from a sick unit into a renowned Kidney Institute of the region. Prior to his stint at Bangalore, Dr Gill successfully led Fortis Mohali to achieve a JCI and NABH accreditation, making it the first hospital in India to do so. In the course of his career, he has attended various prestigious programs linked to healthcare management and accreditations in the US and renowned management institutes in India. Simmar is passionate about running Fortis Hospitals with an aim to deliver top quality healthcare and world class services that Fortis is synonymous with.

Capri Jalota

Mr. Capri Jalota is General Manager - Operations, SRL Diagnostics, UAE of the Company. Capri heads the Business Operations of SRL Diagnostics in Dubai and also supports growth initiatives of the Fortis Group in the region. He has been with the group for over 4 years with an overall experience of over 10 years. He has been instrumental in the growth of diagnostic business especially in newer geographies like KSA, Qatar and Sudan. A Mechanical Engineer with a post graduate in Business Management from the prestigious IIM Ahmedabad (India), Capri is a perseverant 'go-getter' with high result orientation. He has a proven track record of high performance across revenue enhancement, cost reduction, project management & efficiency improvement. Prior to joining Dubai operations, Capri has worked in multiple roles within Fortis. As Director of the Group's 100 bed hospital in Kota, India, he was instrumental in the turnaround of the hospital. He has also worked as Head - Administration in Fortis hospital, Jaipur - a 200 bed tertiary hospital and EA to President (Strategy & OD). He was also part of the first batch of Leadership Development Initiative in Fortis Healthcare - aimed to groom high potential individuals into effective business leaders within the organization. Before joining Fortis, he was Project Manager with Tata Strategic Management Group and led a variety of Management Consulting assignments in the area of Strategy development, Business Planning, Cost Reduction, etc. During the initial days of his career, Capri worked with India's No 1 car maker - Maruti Suzuki Limited in the Quality Assurance Division wherein deep concepts of Quality were ingrained within him. Ever since, he still tries intently to follow those principles and continue his pursuit for excellence. A thorough believer in the power of team work, Capri believes that infinite value can be unlocked by building a cohesive & complimentary team.

Daphne Khoo

Dr. Daphne Khoo is Global Chief Medical Officer of the Company. Dr. Daphne Khoo completed her medical training at the National University of Singapore. She trained in Endocrinology at the Singapore General Hospital and the Cleveland Clinic Foundation, USA. From 2004 to 2011 she was Head of Endocrinology at the Singapore General Hospital. Concurrently, she was also Director of Clinical Governance and Quality Management at Singapore Health Services. She has held leadership positions in the areas of Clinical and Service Quality, Enterprise Risk, Patient Safety and Chronic Disease Management in Singapore's largest healthcare cluster. She is a Past President of the Association of Women Doctors, Singapore, the Endocrine and Metabolic Society, Singapore and the ASEAN Federation of Endocrine Societies. She has published widely and was conferred the Nagataki Distinguished Scientist Award from the Asia-Oceania Thyroid Association in 2007. Dr.Khoo was an adjunct Associate Professor with the Duke-National University of Singapore Medical School.

K. Srivatsan

Mr. K. Srivatsan is Chief Financial Officer of Fortis Healthcare International., the subsidiary of the Company. Srivatsan graduated in Commerce with professional qualifications in Finance, from the Institute of Cost and Works Accountants of India, and Legal, from the Institute of Company Secretaries of India. His overall experience of over 20 years spans pharmaceuticals, healthcare and shipping. Srivatsan has been with Fortis Healthcare since 2011. Prior to joining Fortis Healthcare, he has been with Cipla Limited, Sanofi Aventis Limited, Panacea Biotec Limited, Wockhards Hospitals Limited and Mercator Lines (Singapore) Limited. Srivatsan's dynamic professional career reflects pioneering experience & year-on-year success in achieving business growth objectives. He has cross functional exposure to Finance & Accounting, Technical, Commercial and Medico-Marketing operations. He is a sound business thinker who focuses on operations and pays attention to details while retaining the ability to look at the big picture: business beyond numbers. Srivatsan is a team player and has the ability to multi task and generate ideas and solutions.

Udai Dhawan

Sunil Godhwani

Mr. Sunil Godhwani is Non-Executive Non-Independent Director of the Company. He is a graduate in Chemical Engineering and has a Master’s Degree in Industrial Engineering & Finance from Polytechnic Institute of New York. He has 20 years of experience in business. He is the CEO & Managing Director of Religare Enterprises Limited and the Chairman and Managing Director of Religare Securities Limited.

Harpal Singh

Mr. Harpal Singh is Non-Executive Non-Independent Director of the Company. He graduated with a B.A. (Honors) degree in Economics from St. Stephen’s College, Delhi and holds a B.S. degree in Economics and a Master’s degree in Public Affairs from the California State University at Hayward (C.S.C.H.), California, U.S.A.Further, Mr. Harpal Singh is and has been on the Board of many premier educational institutions, including Doon School and Shriram School, and an Advisory Board Member of the SRM University of Chennai. He is also a Member of the Punjab Education Board. Mr. Harpal Singh has also been a member of several Government Committees and is presently a member of the Punjab Chief Minister’s Advisory Committee on Industrial Growth and Development of Relevant Infrastructure. Mr. Harpal Singh is National Chairman of the CII Committee on Public Health, a member of the CII National Committee on Healthcare and the National Committee on Primary and Secondary Education. Mr. Singh is a Member of the Resource Persons Group for Delhi on Healthcare, appointed by the Lt. Governor of Delhi. Mr. Singh is also a member of the India-UK Round Table and is an invitee speaker in many spheres. He has chaired the 2nd and 3rd India Health Summit in New Delhi and was invited to speak at the Royal Institute of Great Britain on Integrating Global Healthcare. As a member of the US – India Strategic Dialogue in December 2005, he presented a strategic opportunity position for collaboration between the U.S and Indian healthcare systems.

Lynette Brown

Gurcharan Das

Mr. Gurcharan C. Das is Non-Executive Independent Director of the Company. He has graduated with a Bachelor of Arts (Honors) degree cum laude in Philosophy and Government from Harvard University, U.S.A. and holds an MBA degree from Harvard Business School, Harvard University, U.S.A. Mr. Das is an author and a management consultant and advises a number of companies on global corporate strategy. He held the position of the Chief Executive Officer, Procter and Gamble India from 1985 until 1992, and Chairman and Managing Director of Richardson Hindustan Limited from 1981 until 1985. He has over 30 years of experience working in six countries. He is an operating advisor and investor in Chrys Capital LLC. He served on juries of the McKinsey award for Harvard Business Review article for 2005 and the $500,000 Milton Friedman Prize. Mr. Das has served on several Government Boards, including the Foreign Investment Promotion Council in India. He is the author of the book “India Unbound”. He is a regular columnist for the newspapers ‘Times of India’ and the ‘Dainik Bhaskar’ and he contributes occasional articles to the Wall Street Journal and other newspapers.

Joji Gill

Ms. Joji Sekhon Gill is Non-Executive Independent Director of the Copmpany.

Preetinder Joshi

Dr. Preetinder Singh Joshi is Non-Executive Independent Director of the Company. Dr. Joshi, an eminent Cardiologist, has over 32 years of experience in medical profession in India and abroad. Presently, he is working as Director of Maharaj Sawan Singh Charitable Hospital, Beas (Punjab). Dr. Joshi holds an M.B.B.S. degree from Medical College, Amritsar and M.D. degree in Cardiology & General Medicine from Maulana Azad Medical College, Delhi. He is also a member of Royal College of Physicians, UK and American College of Cardiology.

Pradeep Raniga

Mr. Pradeep Ratilal Raniga is Non-Executive Independent Director of the Company.

Brian Tempest

Dr. Brian William Tempest is Non-Executive Independent Director of the Company. He has a PhD from Lancaster University and is a member of the Royal Society of Medicine and the Royal Society of Chemistry. He advises Companies, Banks, Investment Funds, Private Equity & High Net worth Individuals on their Strategy in Asia based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade or more. Dr. Tempest has worked for Ranbaxy Laboratories Limited since 1995 and also held the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has an insight into India. He has worked for Glaxo as Regional Director- Far East and Regional Director- Middle East & Africa. He has worked in the Pharmaceutical Industry for the last 39 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Asia and India. Dr. Tempest has led many sessions at Investor Meetings held around the World. He is an Independent Chairman of Religare Capital Markets which is responsible for the international global banking business of Religare. He is an international advisor to MAPE the Indian M&A boutique and UNCTAD Switzerland. In addition, he is a member of the SCRIP Global Awards Panel and is on the Editorial Board of the Journal of Generic Medicines. He speaks at global conferences on the challenges from India and China. He is a Chairman of Hale & Tempest Co. Ltd.

Anurag Kalra

Search Stocks